Impact of Antibiotic-Resistant Bacteria on the Outcome of Ventilator-Associated Pneumonia

ABSTRACT

Since antibiotic resistance has become a worldwide concern, there has been an ongoing debate as to whether infections caused by resistant bacteria are associated with higher mortality. Because resistant strains do not appear to be more virulent, differences in outcome may principally relate to patients' characteristics before or at the time of infection onset, and to high rates of inappropriate empirical antimicrobial treatment prescribed for antibiotic-resistant infections. In two large series of severe Staphylococcus aureus and Pseudomonas aeruginosa ventilator-associated pneumonia, we recently demonstrated that antibiotic resistance does not significantly affect intensive care unit mortality of patients receiving appropriate initial antibiotics. However, antibiotic resistance was consistently found to increase hospital length of stay. Early identification of patients with risk factors favoring antibiotic-resistant infections should prompt the initiation of an empirical antibiotic regimen covering these highly resistant bacteria, which can usually be deescalated 48 to 72 hours later when the results of microbiological samples culture become available.

KEYWORDS

Ventilator-associated pneumonia - Staphylococcus aureus - Pseudomonas aeruginosa - resistant organisms - treatment outcome

REFERENCES

• 1 Jevons M P. Celbin-resistant staphylococci.  BMJ. 1961;  1 124-125
• 2 National Nosocomial Infections Surveillance (NNIS) System Report . Data summary from January 1992 through June 2004, issued October 2004.  Am J Infect Control. 2004;  32 470-485
• 3 Chastre J, Trouillet J L. Problem pathogens (Pseudomonas aeruginosa and Acinetobacter).  Semin Respir Infect. 2000;  15 287-298
• 4 Romero-Vivas J, Rubio M, Fernandez C et al.. Mortality associated with nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus .  Clin Infect Dis. 1995;  21 1417-1423
• 5 Pujol M, Pena C, Pallares R et al.. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains.  Am J Med. 1996;  100 509-516
• 6 Steinberg J P, Clark C C, Hackman B O. Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance.  Clin Infect Dis. 1996;  23 255-259
• 7 Rello J, Torres A, Ricart M et al.. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes.  Am J Respir Crit Care Med. 1994;  150 1545-1549
• 8 Blot S I, Vandewoude K H, Hoste E A et al.. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus .  Arch Intern Med. 2002;  162 2229-2235
• 9 Talon D, Woronoff-Lemsi M C, Limat S et al.. The impact of resistance to methicillin in Staphylococcus aureus bacteremia on mortality.  Eur J Intern Med. 2002;  13 31-36
• 10 Engemann J J, Carmeli Y, Cosgrove S E et al.. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection.  Clin Infect Dis. 2003;  36 592-598
• 11 Cosgrove S E, Sakoulas G, Perencevich E N et al.. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.  Clin Infect Dis. 2003;  36 53-59
• 12 Harbarth S, Rutschmann O, Sudre P et al.. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus .  Arch Intern Med. 1998;  158 182-189
• 13 Tumbarello M, De Gaetano Donati K, Tacconelli E et al.. Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients.  J Antimicrob Chemother. 2002;  50 375-382
• 14 Soriano A, Martinez J A, Mensa J et al.. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia.  Clin Infect Dis. 2000;  30 368-373
• 15 Mylotte J M, Tayara A. Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort.  Clin Infect Dis. 2000;  31 1170-1174
• 16 French G L, Cheng A F, Ling J M et al.. Hong Kong strains of methicillin-resistant and methicillin-sensitive Staphylococcus aureus have similar virulence.  J Hosp Infect. 1990;  15 117-125
• 17 Selvey L A, Whitby M, Johnson B. Nosocomial methicillin-resistant Staphylococcus aureus bacteremia: is it any worse than nosocomial methicillin-sensitive Staphylococcus aureus bacteremia?.  Infect Control Hosp Epidemiol. 2000;  21 645-648
• 18 Raymond D P, Pelletier S J, Crabtree T D et al.. Impact of antibiotic-resistant gram-negative bacilli infections on outcome in hospitalized patients.  Crit Care Med. 2003;  31 1035-1041
• 19 Trouillet J L, Vuagnat A, Combes A et al.. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms.  Clin Infect Dis. 2002;  34 1047-1054
• 20 Blot S, Vandewoude K, De Bacquer D et al.. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization.  Clin Infect Dis. 2002;  34 1600-1606
• 21 Carmeli Y, Troillet N, Karchmer A W et al.. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa .  Arch Intern Med. 1999;  159 1127-1132
• 22 Cosgrove S E, Kaye K S, Eliopoulous G M et al.. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species.  Arch Intern Med. 2002;  162 185-190
• 23 Bjorkman J, Nagaev I, Berg O G et al.. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance.  Science. 2000;  287 1479-1482
• 24 Hewitt J H, Sanderson P J. The effect of methicillin on skin lesions in guinea-pigs caused by methicillin-sensitive and methicillin-resistant Staphylococcus aureus .  J Med Microbiol. 1974;  7 223-235
• 25 Peacock Jr J E, Moorman D R, Wenzel R P et al.. Methicillin-resistant Staphylococcus aureus: microbiologic characteristics, antimicrobial susceptibilities, and assessment of virulence of an epidemic strain.  J Infect Dis. 1981;  144 575-582
• 26 Aathithan S, Dybowski R, French G L. Highly epidemic strains of methicillin-resistant Staphylococcus aureus not distinguished by capsule formation, protein A content or adherence to HEp-2 cells.  Eur J Clin Microbiol Infect Dis. 2001;  20 27-32
• 27 Schmitz F J, MacKenzie C R, Geisel R et al.. Enterotoxin and toxic shock syndrome toxin-1 production of methicillin resistant and methicillin sensitive Staphylococcus aureus strains.  Eur J Epidemiol. 1997;  13 699-708
• 28 Laurent F, Lelievre H, Cornu M et al.. Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals.  J Antimicrob Chemother. 2001;  47 277-283
• 29 Duckworth G J, Jordens J Z. Adherence and survival properties of an epidemic methicillin-resistant strain of Staphylococcus aureus compared with those of methicillin-sensitive strains.  J Med Microbiol. 1990;  32 195-200
• 30 Ellis M W, Hospenthal D R, Dooley D P et al.. Natural history of community-acquired methicillin-resistant Staphylococcus aureus colonization and infection in soldiers.  Clin Infect Dis. 2004;  39 971-979
• 31 Cosgrove S E, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes.  Clin Infect Dis. 2003;  36 1433-1437
• 31a Mc Cabe W R, Jackson G G. Gram-negative bacteremia.  Arch Intern Med. 1962;  110 847-864
• 32 Charlson M E, Pompei P, Ales K L et al.. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.  J Chronic Dis. 1987;  40 373-383
• 33 Levine D P, Fromm B S, Reddy B R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis.  Ann Intern Med. 1991;  115 674-680
• 34 Cruciani M, Gatti G, Lazzarini L et al.. Penetration of vancomycin into human lung tissue.  J Antimicrob Chemother. 1996;  38 865-869
• 35 Lamer C, de Beco V, Soler P et al.. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.  Antimicrob Agents Chemother. 1993;  37 281-286
• 36 Rodman D P, McKnight J T, Rogers T et al.. The appropriateness of initial vancomycin dosing.  J Fam Pract. 1994;  38 473-477
• 37 Conte Jr J E, Golden J A, Kipps J et al.. Intrapulmonary pharmacokinetics of linezolid.  Antimicrob Agents Chemother. 2002;  46 1475-1480
• 38 Wunderink R G, Rello J, Cammarata S K et al.. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.  Chest. 2003;  124 1789-1797
• 39 Stevens D L, Herr D, Lampiris H et al.. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.  Clin Infect Dis. 2002;  34 1481-1490
• 40 Levin A S, Barone A A, Penco J et al.. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii .  Clin Infect Dis. 1999;  28 1008-1011
• 41 Kang C I, Kim S H, Park W B et al.. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome.  Antimicrob Agents Chemother. 2005;  49 760-766
• 42 Roghmann M C. Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia.  Arch Intern Med. 2000;  160 1001-1004
• 43 Gonzalez C, Rubio M, Romero-Vivas J et al.. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms.  Clin Infect Dis. 1999;  29 1171-1177
• 44 Kollef M H, Sherman G, Ward S et al.. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.  Chest. 1999;  115 462-474
• 45 Lentino J R, Hennein H, Krause S et al.. A comparison of pneumonia caused by gentamicin, methicillin-resistant and gentamicin, methicillin-sensitive Staphylococcus aureus: epidemiologic and clinical studies.  Infect Control. 1985;  6 267-272
• 46 Combes A, Luyt C E, Fagon J Y et al.. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2004;  170 786-792
• 47 Zahar J R, Clec'h C, Tafflet M et al.. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia?.  Clin Infect Dis. 2005;  41 1224-1231
• 48 Shorr A F, Combes A, Kollef M H et al.. Methicillin resistant Staphylococcus aureus prolongs intensive care unit length of stay in ventilator-associated pneumonia despite initially appropriate antibiotic therapy.  Crit Care Med. 2005;  , In press
• 49 Chastre J, Wolff M, Fagon J Y et al.. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.  JAMA. 2003;  290 2588-2598
• 50 Luyt C E, Combes A, Trouillet J L et al.. Impact of piperacillin resistance on the outcome of Pseudomonas aeruginosa ventilator-associated pneumonia [abstract].  Am J Respir Crit Care Med. 2005;  171 A819